Page 100 - Read Online

Page 12 of 14 Porcari et al. Vessel Plus 2022;6:33 https://dx.doi.org/10.20517/2574-1209.2021.134

Council on Clinical Cardiology. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the american
heart association. Circulation 2020;142:e7-e22. DOI PubMed
22. Knight DS, Zumbo G, Barcella W, et al. Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic
resonance and echocardiography and their prognostic roles. JACC Cardiovasc Imaging 2019;12:823-33. DOI PubMed
23. Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll
Cardiol 2016;68:1323-41. DOI PubMed
24. Rapezzi C, Lorenzini M, Longhi S, et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev 2015;20:117-24. DOI PubMed
25. Canepa M, Tini G, Musumeci B, et al. Real-world versus trial patients with transthyretin amyloid cardiomyopathy. Eur J Heart Fail
2019;21:1479-81. DOI PubMed
26. Tini G, Cappelli F, Biagini E, et al. Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey.
ESC Heart Fail 2021;8:3369-74. DOI PubMed PMC
27. Aimo A, Vergaro G, Castiglione V, Rapezzi C, Emdin M. Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis.
Eur J Intern Med 2020;80:66-72. DOI PubMed
28. Aus dem Siepen F, Hein S, Bauer R, Katus HA, Kristen AV. Standard heart failure medication in cardiac transthyretin amyloidosis:
useful or harmful? Amyloid 2017;24:132-3. DOI PubMed
29. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and
management of cardiac amyloidosis. Circulation 2017;135:1357-77. DOI PubMed PMC
30. Mints YY, Doros G, Berk JL, Connors LH, Ruberg FL. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a
systematic review and clinical experience. ESC Heart Fail 2018;5:772-9. DOI PubMed PMC
31. Donnellan E, Wazni OM, Hanna M, et al. Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of
rhythm control strategies. JACC Clin Electrophysiol 2020;6:1118-27. DOI PubMed
32. Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation
2007;116:2420-6. DOI PubMed
33. Hindricks G, Potpara T, Dagres N, et al; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of
atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for
the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special
contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373-498. DOI PubMed
34. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981;63:1285-8. DOI PubMed
35. Muchtar E, Gertz MA, Kumar SK, et al. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?
Amyloid 2018;25:86-92. DOI PubMed PMC
36. Cheung CC, Roston TM, Andrade JG, Bennett MT, Davis MK. Arrhythmias in cardiac amyloidosis: challenges in risk stratification
and treatment. Can J Cardiol 2020;36:416-23. DOI PubMed
37. Gertz MA, Skinner M, Connors LH, Falk RH, Cohen AS, Kyle RA. Selective binding of nifedipine to amylold fibrils. Am J Cardiol
1985;55:1646. DOI PubMed
38. Gertz MA, Falk RH, Skinner M, Cohen AS, Kyle RA. Worsening of congestive heart failure in amyloid heart disease treated by
calcium channel-blocking agents. Am J Cardiol 1985;55:1645. DOI PubMed
39. Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, et al. High prevalence of intracardiac thrombi in cardiac amyloidosis. J Am Coll
Cardiol 2019;73:1733-4. DOI PubMed
40. El-Am EA, Dispenzieri A, Melduni RM, et al. Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. J
Am Coll Cardiol 2019;73:589-97. DOI PubMed PMC
41. Loungani RS, Rehorn MR, Geurink KR, et al. Outcomes following cardioversion for patients with cardiac amyloidosis and atrial
fibrillation or atrial flutter. Am Heart J 2020;222:26-9. DOI PubMed
42. Tan NY, Mohsin Y, Hodge DO, et al. Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis. J Cardiovasc
Electrophysiol 2016;27:1167-73. DOI PubMed
43. Barbhaiya CR, Kumar S, Baldinger SH, et al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias
associated with amyloid cardiomyopathy. Heart Rhythm 2016;13:383-90. DOI PubMed
44. Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018;39:2799-806.
DOI PubMed
45. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with
bradycardia and cardiac conduction delay: executive summary: a report of the American College of Cardiology/American Heart
Association task force on clinical practice guidelines, and the heart rhythm society. J Am Coll Cardiol 2019;74:932-87. DOI PubMed
46. Donnellan E, Wazni OM, Saliba WI, et al. Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left
ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol 2019;30:2427-32. DOI PubMed
47. Dubrey S, Pollak A, Skinner M, Falk RH. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial
electromechanical dissociation. Br Heart J 1995;74:541-4. DOI PubMed PMC
48. Cappelli F, Tini G, Russo D, et al. Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. Amyloid
2021;28:12-8. DOI PubMed
49. Yarmohammadi H, Varr BC, Puwanant S, et al. Role of CHADS score in evaluation of thromboembolic risk and mortality in patients
2
with atrial fibrillation undergoing direct current cardioversion (from the ACUTE Trial Substudy). Am J Cardiol 2012;110:222-6. DOI